The Real Value in Value Investing

Wesley Gray |

Book-to-Market Equity, Distress Risk, and Stock Returns, by Griffin and Lemmon (2002 Journal of Finance) investigates the relationship between value premiums and distress risk. There are two schools of thought on the value premium (the large spread in realized returns between cheap stocks and expensive stocks). On the one hand, there is the “risk-based” story for the value premium, which suggests that value stocks are subject to higher risk of distress. On the other hand, the “mispricing story,” which suggests that investors overreact to recent bad news and undervalue cheap stocks, and overreact to recent good news and overvalue expensive stocks. This paper investigates the alternative hypotheses and lets the data speak for itself.

Bottomline: The spread in returns between cheap and expensive firms, given they are classified as “high distress,” is almost double the traditional value premium. And much of the return is driven by expectation changes around earnings announcements (that is, the market is “surprised” by how well the cheap high distress firms do). In short, a win for value investing.

Highest distress risk, as proxied by Ohlson’s (1980) O-score, which is described below:

The_Variable_O_Score.jpg

According to O-Score metrics, growth stocks (e.g., low B/M) have similar distress risk when compared with cheap stocks (e.g., high B/M). In the extreme distress category (marked in blue below), cheap stocks are much less distressed than the expensive stocks. This empirical finding is puzzling for the “risk-based” argument for the value premium, since expensive stocks are actually more distressed on average than cheap stocks, in the extreme distress category. Weird.

Table_I.jpg
Distress_Probability.jpg

The results are hypothetical results and are NOT an indicator of future results and do NOT represent returns that any investor actually attained. Indexes are unmanaged, do not reflect management or trading fees, and one cannot invest directly in an index. Additional information regarding the construction of these results is available upon request.

But perhaps the most extreme distress firms have odd return patterns that can explain this anomaly through the lens of rational asset pricing?

Not Exactly…

In the table below, the authors tabulate the annual B&H returns associated with various cuts on distress and value. Value investing always wins, even after controlling for distress. And value investing REALLY wins among the most distressed firms. Oddly enough, expensive firms that are distressed earn 14.44% LESS than cheap firms that are distressed. So given equivalent distress levels, or “risk,” we should see similar returns…

Table_II.jpg
Distress___Cheap_7_9.jpg

The results are hypothetical results and are NOT an indicator of future results and do NOT represent returns that any investor actually attained. Indexes are unmanaged, do not reflect management or trading fees, and one cannot invest directly in an index. Additional information regarding the construction of these results is available upon request.

Time to avoid the noise and get back to value investing!

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

VOIP PAL.COM INC

VOIP-PAL COM Inc is a development stage company. The Company is engaged in broadband Voice-over-Internet Protocol ("VoIP") market with the ownership and continuing development of a portfolio of VoIP Patents.

Private Markets

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…